AVR anteris technologies global corp.

6.09%

$6.27

IMO - they have both eyes. All the doctors know within minutes...

First 14 Last

Share
Profile

Follow
Eire2011

3,108 Posts.

1925

21/06/22

20:18

Post #: 62122401
Share

Originally posted by Biljor: ↑

just my opinion, I think everyone has one eye on us for sure.
our studies are a double edged sword. we have chosen patients that are so sick they wouldn't meet the grade for US studies. ballsy and very impressive, yes. flip side is until we see technical data, we don't know what the %'s mean.
the study I referred to had an average base line of 295 meters and on "healthier" patients which general fitness could be argued less variable for improvement. then again, that may be the complete opposite and our results are better than what we read. we won't know until the technical data is released. this doesn't diminish our announcement, it's fantastic every way you read it.

IMHO the big boys are attentively observing and will be looking for the technical data at 12 months on all the trial patients, plus the FDA trial etc. a simple reason for this is at 12 months both valves had a patient slight decline in 6MWT. any stability or improvement at 12 months IMO would put us in a very powerful position.

GLTAL

Expand

IMO - they have both eyes.
All the doctors know within minutes of placing the valve that this is “different”. The competition knows it as well.

AVR Price at posting: $23.00 Sentiment: Buy Disclosure: Held
18 Upvote

1 Great analysis

Reply

Top Stories

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

First 14 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $6.27		Change 0.360(6.09%)		Mkt cap ! $97.17M

Open	High	Low	Value	Volume
$5.93	$6.30	$5.91	$107.9K	17.39K

Buyers (Bids)

No.	Vol.	Price($)
1	3500	$6.12

Sellers (Offers)

Price($)	Vol.	No.
$6.27	200	1

View Market Depth

No.	Vol.	Price($)
1	3500	6.120
1	2000	6.100
1	1000	6.000
1	1250	5.950
1	857	5.830

Price($)	Vol.	No.
6.270	200	1
6.300	463	1
6.400	130	1
6.500	255	1
6.550	1092	1

Last trade - 15.42pm 27/06/2025 (20 minute delay)

AVR (ASX) Chart

IMO - they have both eyes. All the doctors know within minutes...

Boss extends June win streak with boosted Alta Mesa extraction rates

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

IMO - they have both eyes. All the doctors know within minutes...

Top Stories

Boss extends June win streak with boosted Alta Mesa extraction rates

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News